Medical Communications

Showing 15 posts of 6402 posts found.

cmglee_cambridge_cancer_research_web

UK oral cancer rates soar 68% over two decades

November 29, 2016 Manufacturing and Production, Medical Communications, Research and Development Cancer Research UK, Oral cancer, mouth cancer

As a move to raise awareness during Mouth Cancer Action Month, Cancer Research UK (CRUK) has released figures of an …
shutterstock_57369385

Biosimilars and Generics: A no-brainer for treatment?

November 28, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biosimilars, generics

The industry is poised on the potential widespread adoption of many revolutionary technologies; foremost among them are biosimilars and generics, …
uday_baldota

Taro announces appointment of new CEO

November 25, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Taro pharmaceutical, sun pharmaceutical

Taro Pharmaceutical announced that Uday Baldota will take up the position of CEO and will begin the role in early …
top_ten_1

Top Ten most popular articles on Pharmafile this week

November 25, 2016 Medical Communications November, news, pharmaceutical, top 10, top ten, top ten stories

This week has seen the pharmaceutical industry return to business as usual after the presidential election provided a boost to …
deb_lancaster

Insider interview: Roche discusses efficacy of CDF and NICE

November 25, 2016 Medical Communications, Sales and Marketing CDF, NICE, Roche

Deborah Lancaster, Head of Market Access at Roche, discusses, in the latest issue of Pharmafile, the efficacy of the National …
nice_aerial

Lowered price wins NICE approval for Janssen leukaemia treatment

November 25, 2016 Medical Communications, Sales and Marketing Janssen, NICE, SMC, chronic lymphocytic leukaemia, ibrutinib, imbruvica

After being knocked back in the beginning of June this year, NICE has announced that Janssen’s Imbruvica (ibrutinib) will now …
bristol

Opdivo first PD-1 inhibitor given European approval for haematological cancer

November 25, 2016 Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, PD1-Inhibitor, bristol myers-squibb

Bristol-Myers Squibb announced that it has received the first and only European approval for a PD1 inhibitor in the treatment …
celgene_1_02

NICE u-turns on Celgene’s drug for multiple myeloma

November 24, 2016 Medical Communications Celgene, NICE, imnovid

NICE has performed a U-turn on Celgene’s Imnovid (pomalidomide) based on new data and the offer of a price reduction. …
shutterstock_231613360

Non-small cell lung cancer market to hit $26bn by 2025

November 24, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GlobalData, non-small cell lung cancer

New research from GlobalData has indicated that the non-small cell lung cancer (NSCLC) market will rise in value by over …
navidea_cmyk

Navidea agrees deal worth $310 million with Cardinal

November 24, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cardinal, Navidea, Navidea biopharmaceutical

Navidea Biopharmaceuticals, a developer of immunodiagnostic agents and immunotherapeutics, has announced that they will enter into a definitive asset purchase …
juno

Patient deaths lead Juno Therapeutics to halt trial for second time

November 24, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing acute lymphoblastic leukaemia, clinical trial deaths, juno therapeutics

Juno Therapeutics has been forced to halt a trial investigating the efficacy of its lead experimental CAR-T cancer treatment JCAR015 …
lilly2_web

Lilly forced to abandon Alzheimer’s drug after failed trial

November 24, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Alzheimer's disease, Eli Lilly

Eli Lilly announced that the results of its ‘Expedition 3’ trial for an experimental Alzheimer’s disease drug meant that they would …
allergan

Allergan acquires Chase Pharma in potential $1 billion deal

November 23, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Allergan announced that it has completed the acquisition of Chase Pharmaceutical Corporation in a deal worth a potential $1 billion. …
anthony_maddaluna

Anthony Maddaluna, executive vice president of Pfizer, to retire

November 23, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Anthony J. Maddaluna, who worked at Pfizer for more than 41 years, will retire from his positions of executive vice …

Scientists identify an existing drug that could aid in therapy for brain swelling

November 23, 2016 Medical Communications, Research and Development University of Arkansas, concussion, head injury

A team of biomedical engineering researches, who performed their study at the University of Arkansas, have identified a drug that …
The Gateway to Local Adoption Series

Latest content